CERO THERAPEUTICS HOLDINGS, INC. (CERO) Form 424B3 — May 15, 2026
Cero Therapeutics Holdings, Inc. filed a prospectus supplement updating its S-1 registration statement with its Q1 2026 10-Q results. The filing reveals severe financial distress, with the company reporting a net loss of $5.9 million and a working capital deficit of approximately $9.8 million for the quarter ended March 31, 2026. The company holds only $857,489 in cash and cash equivalents, leading management to state that these conditions raise substantial doubt about its ability to continue as a going concern.
Key figures
- Revenue
- 0
- Total Debt
- 11463865
- Cash Position
- 857489
- Shares Outstanding
- 36010373
- Stock Price
- 0.027
- Warrant Price
- 0.0038
- Accumulated Deficit
- 96724029
- Stockholders Deficit
- 9258755
- Working Capital Deficit
- 9800000
- Net Cash Used In Operations
- 2800000
- Potential Dilutive Shares
- 294373486
- Recent Financing Proceeds
- 1956166
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.